Menveo Market Report 2026

Menveo Market Overview

• The Menveo market growth in the historic period has been driven by expansion of national immunization schedules, historical outbreaks of meningococcal disease • Market expansion is supported by growing investments in vaccine innovation, rising focus on outbreak prevention • Growth Driver: Increase In Meningitis Cases Fueling Demand For Menveo Vaccine • Market Trend: Innovative Vaccine Formulations Driving Market Trends • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Menveo Market?

Menveo is a meningococcal vaccine that protects against infections caused by Neisseria meningitidis. It targets serogroups A, C, W, and Y, which can cause meningitis and bloodstream infections. The vaccine is recommended for adolescents, young adults, and individuals at higher risk of meningococcal disease. The main vaccine types of menveo are conjugate vaccine and combination vaccine. A conjugate vaccine combines a bacterial protein with a polysaccharide (sugar molecule) to enhance the immune response. This combination helps the immune system recognize and attack the bacteria more effectively. It is indicated for various purposes, including meningococcal disease prevention, routine immunization, outbreak control, and travel vaccination. Menveo is used for different age groups, including infants and young children, adolescents, adults, and older adults. The end users include hospitals, vaccination clinics, travel clinics, academic and research institutions, and military and government facilities.

What Is The Menveo Market Growth Forecast?

The growth in the forecast period can be attributed to growing investments in vaccine innovation, rising focus on outbreak prevention, expansion of adult and adolescent immunization coverage, increasing travel-related vaccination demand, strengthening of public health infrastructure. Major trends in the forecast period include increasing adoption of conjugate vaccines, rising focus on preventive immunization programs, growing demand for adolescent and travel vaccination, expansion of multivalent vaccine coverage, enhanced emphasis on public health preparedness.

Global Menveo Market Segmentation

1) By Type of Vaccine: Conjugate Vaccine, Combination Vaccine 2) By Indication: Meningococcal Disease Prevention, Routine Immunization, Outbreak Control, Travel Vaccination 3) By Age Group: Infants and Young Children, Adolescents, Adults, Older Adults 4) By End User: Hospitals, Vaccination Clinics, Travel Clinics, Academic And Research Institutions, Military And Government Facilities

What Are The Drivers Of The Menveo Market?

The increasing prevalence of meningitis is expected to propel the growth of the menveo market going forward. Meningitis is an infection that causes inflammation of the protective membranes surrounding the brain and spinal cord, typically triggered by viral, bacterial, or fungal pathogens. The rise in meningitis prevalence is primarily driven by factors such as increasing global mobility and weakened immune systems, which heighten the risk of disease transmission. Menveo supports public health efforts by providing protection against multiple strains of Neisseria meningitidis, enabling early prevention, reducing disease spread, and lowering the burden of invasive meningococcal infections. For instance, in October 2025, according to the UK Health Security Agency, a UK-based government agency, A total of 378 invasive meningococcal disease (IMD) cases were confirmed in 2024–25. Therefore, the increasing prevalence of meningitis is driving the growth of the menveo industry. The global expansion of healthcare infrastructure is expected to propel the growth of the menveo going forward. Healthcare infrastructure refers to the physical and organizational structures, facilities, resources, and systems necessary for delivering healthcare services to a population. Several key factors, including the aging global population, the increase in chronic diseases, and technological advancements, drive healthcare infrastructure expansion. Menveo is a meningococcal vaccine that protects patients from invasive meningococcal disease, leveraging healthcare infrastructure through vaccination programs in clinics, hospitals, and public health initiatives. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, marking a significant rise compared to the 0.9% growth seen in 2022. Therefore, the global expansion of healthcare infrastructure is driving the growth of the menveo industry.

Key Players In The Global Menveo Market

Major companies operating in the menveo market are GlaxoSmithKline (GSK) Plc

Global Menveo Market Trends and Insights

The key trend in the menveo market is developing innovative vaccine formulations, such as single-vial, fully liquid formulations, to enhance convenience, improve stability, and simplify vaccine administration. Single-vial, fully liquid formulations refer to pharmaceutical products that are pre-mixed and packaged in a single vial, with the active ingredients dissolved in a liquid form, ready for administration. For instance, in November 2024, GlaxoSmithKline (GSK) plc, a UK-based pharmaceutical industry company, received approval from the European Commission (EC) for a new presentation of its meningococcal vaccine, Menveo for active immunization against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y. The vaccine is now licensed for use in children aged two years and older, adolescents, and adults. The key features of the approval for the vaccine include its licensing for active immunization in the European Union for children from two years of age, adolescents, and adults, with a new single-vial, fully liquid presentation that eliminates the need for reconstitution before use.

Regional Insights

North America was the largest region in the menveo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Menveo Market?

The menveo market consists of sales of prefilled syringes, powders for suspension, combination vaccines, booster doses, and single-dose vials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Menveo Market Report 2026?

The menveo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the menveo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.